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Abstract
Background: The rs12807809 single-nucleotide polymorphism in NRGN is a genetic risk variant with genome-wide
significance for schizophrenia. The frequency of the T allele of rs12807809 is higher in individuals with schizophrenia than in
those without the disorder. Reduced immunoreactivity of NRGN, which is expressed exclusively in the brain, has been
observed in Brodmann areas (BA) 9 and 32 of the prefrontal cortex in postmortem brains from patients with schizophrenia
compared with those in controls.
Methods: Genotype effects of rs12807809 were investigated on gray matter (GM) and white matter (WM) volumes using
magnetic resonance imaging (MRI) with a voxel-based morphometry (VBM) technique in a sample of 99 Japanese patients
with schizophrenia and 263 healthy controls.
Results: Although significant genotype-diagnosis interaction either on GM or WM volume was not observed, there was a
trend of genotype-diagnosis interaction on GM volume in the left anterior cingulate cortex (ACC). Thus, the effects of NRGN
genotype on GM volume of patients with schizophrenia and healthy controls were separately investigated. In patients with
schizophrenia, carriers of the risk T allele had a smaller GM volume in the left ACC (BA32) than did carriers of the non-risk C
allele. Significant genotype effect on other regions of the GM or WM was not observed for either the patients or controls.
Conclusions: Our findings suggest that the genome-wide associated genetic risk variant in the NRGN gene may be related
to a small GM volume in the ACC in the left hemisphere in patients with schizophrenia.
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Introduction
Schizophrenia is a common and complex psychiatric disorder
that has a strong genetic component; the estimated heritability is
81% [1]. Many genes have been implicated in the pathogenesis of
schizophrenia [2].
A genome-wide association study (GWAS) of single-nucleotide
polymorphisms (SNPs) conducted by accessing thousands of DNA
samples from patients and controls can be a powerful tool for
identifying common risk factors for such a complex disease.
Stefansson et al. examined a combined sample of 12,945 patients
with schizophrenia and 34,591 controls from three large GWASs
(the SGENE-plus, the International Schizophrenia Consortium
and the Molecular Genetics of Schizophrenia) and a follow-up
with 4,999 patients and 15,555 controls from four additional
sample sets from various areas of Europe (including the Nether-
lands, Denmark, Germany, Hungary, Norway, Russia, Sweden,
Finland and Spain) [3]. The researchers identified several
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than the genome-wide significance threshold of approximately
1.6610
27 in the combined samples. Five of these markers—
rs6913660, rs13219354, rs6932590, rs13211507 and rs3131296—
span the major histocompatibility complex (MHC) region on
chromosome 6p21.3–22.1; one marker, rs12807809, is located
3,457 bases upstream from the neurogranin (NRGN) gene on
11q24.2; one additional marker, rs9960767, is located in intron
four of the transcription factor 4 (TCF4) gene on 18q21.2. Of these
seven SNPs, four SNPs, rs6913660, rs13219354, rs13211507 and
rs9960767, were not polymorphic in samples from the HapMap
Japanese in Tokyo (JPT) project. Minor allele frequencies (MAF)
of two SNPs, rs6932590 and rs3131296, were under 5%. Because
only one marker, rs12807809 in NRGN, was a common SNP in
HapMap JPT samples (MAF.5%), we focused on this SNP in the
present study.
NRGN is the human homolog of the neuron-specific rat gene
RC3/neurogranin. NRGN encodes a postsynaptic protein kinase
substrate that binds to calmodulin (CaM) in the absence of calcium
[4]. The NRGN gene spans 7.3 kb of genomic DNA and contains
four exons that transcribe a protein of 78 amino acids [5]. Exons 1
and 2 encode the protein, and exons 3 and 4 contain untranslated
sequences. NRGN plays an important role in the Ca
2+–CaM
signaling pathway [6]. A Ca
2+ influx-induced oxidation of NRGN
leads to postsynaptic activation of CaM-dependent protein kinase
II (CaMKII) by CaM, which is associated with strengthened N-
methyl-D-aspartate (NMDA) receptor signaling [7]. Altered
NRGN activity may therefore mediate the effects of the NMDA
hypofunction implicated in the pathophysiology of schizophrenia.
Many attempts have been made to minimize clinical and
genetic heterogeneity in studies of schizophrenia. One strategy for
gene discovery uses neurobiological quantitative traits (QT) as
intermediate phenotypes rather than the diagnosis of schizophre-
nia [8,9]. This strategy has the potential to reduce clinical and
genetic heterogeneity by examining intermediate phenotypes that
reflect underlying genetic vulnerability better than diagnostic
categorization [10]. Structural brain phenotypes are QT that show
considerable variation in human populations [11]. A voxel-wise
meta-analysis of gray matter (GM) alterations in patients with
schizophrenia indicated that they had a reduced GM density in
the bilateral insular cortex, anterior cingulate, left parahippocam-
pal gyrus, left middle frontal gyrus, postcentral gyrus, and
thalamus and had an increased GM density in the striatal regions
relative to the control subjects [12]. A voxel-wise meta-analysis of
white matter (WM) alterations in patients with schizophrenia
indicated that these patients had a decreased WM volume in the
frontal regions and internal capsule relative to control subjects
[13]. Heritability estimates indicate a moderate (40–70%) to high
(70–95%) genetic influence on brain structure volumes in the
frontal and temporal brain regions, such as the middle frontal and
the anterior cingulate cortices [11,14]. Some studies have shown
that abnormalities in brain structure are intermediate phenotypes
that bridge the gap between the genotype and diagnostic
categorization [10,15,16]. Our research group has a long-standing
interest in the effects of genetic variants on brain structure
(i.e., COMT, DISC1, PACAP, BDNF, APOE and AKT1) [17,18,
19,20,21,22] and on prefrontal activity as measured by near-
infrared spectroscopy (NIRS) (TBP and SIGMAR1) in psychiatric
disorders [23,24]. NRGN is expressed exclusively in the brain,
especially in the dendritic spines. Reduced NRGN immunoreac-
tivity has been observed in prefrontal areas 9 and 32 of post-
mortem schizophrenic brains [25]. To date, no study has
investigated the effects of the NRGN polymorphism and the
genotype-diagnosis interaction on brain morphology at the whole
brain level. In this study, we examined the impacts of the NRGN
polymorphism and the genotype-diagnosis interaction on GM
volumes and WM volumes in patients with schizophrenia and in
healthy volunteers.
Materials and Methods
Ethics statement
Written informed consent was obtained from all subjects after
the procedures had been fully explained. This study was carried
out in accordance with the World Medical Association’s
Declaration of Helsinki and approved by the Research Ethical
Committee of Osaka University.
Subjects
Voxel-based morphometry(VBM) analyses were conducted on 99
patients with schizophrenia [52.5% males (52 males and 47 females);
mean age 6 SD, 38.4612.9 years] and 263 healthy controls [44.5%
males (117 males and 146 females); mean age 6 SD, 36.7611.6
years]. All subjects were biologically unrelated within the second-
degree of relationship and of Japanese descent [23,26]. The subjects
were excluded if they had neurological or medical conditions that
could potentially affect the central nervous system, such as atypical
headache, head trauma with loss of consciousness, chronic lung
disease, kidney disease, chronic hepatic disease, thyroid disease,
active cancer, cerebrovascular disease, epilepsy, seizures, substance-
related disorders or mental retardation. Cases were recruited from
the university hospital. Each patient with schizophrenia had been
diagnosed by at least two trained psychiatrists according to the
criteria of the Diagnostic and Statistical Manual of Mental Disorders, Fourth
Edition (DSM-IV) based on the Structured Clinical Interview for
DSM-IV (SCID). Controls were recruited through local advertise-
ments at Osaka University. Psychiatrically, medically and neurolog-
ically healthy controls were evaluated using the non-patient version
of the SCID to exclude individuals who had current or past contact
with psychiatricservices orwho hadreceived psychiatricmedication.
Current symptoms of schizophrenia were evaluated using the
positive and negative syndrome scale (PANSS) [27]. Mean age, sex
ratio and handedness did not differ significantly between cases and
controls (p.0.17), while the years of education, estimated premorbid
intelligence quotient (IQ) and GM volumes were significantly lower
in the patients with schizophrenia than in the controls (p,0.001)
(Table S1). When the genotype groups were compared, we found no
differences in the demographic variables, except for years of
education and duration of illness in patients with schizophrenia
(Table S1).
SNP selection and SNP genotyping
We selected rs12807809 in the NRGN gene as described in the
introduction. This polymorphism is reported as T/C and was
previously described in the GWAS [3]. Venous blood was collected
from the subjects, and genomic DNA was extracted from whole
blood according to standard procedures. The SNP was genotyped
using the TaqMan 59-exonuclease allelic discrimination assay (Assay
ID: C__32029000_20, Applied Biosystems, Foster City, California,
USA) as previously described [18,19]. Detailed information on the
PCR conditions is available upon request. No deviation from Hardy-
Weinberg equilibrium (HWE) in the examined SNP was detected in
the patients or in the controls (p.0.05).
Magnetic resonance imaging procedure
All magnetic resonance (MR) studies were performed on a 1.5T
GE Sigma EXCITE system. A three-dimensional volumetric
acquisition of a T1-weighted gradient echo sequence produced a
Impact of NRGN on Brain Structure in Schizophrenia
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recalled acquisition in the steady state (SPGR) sequence (TE/TR,
4.2/12.6 ms; flip angle, 15u; acquisition matrix, 2566256; 1NEX,
FOV, 24624 cm; slice thickness, 1.4 mm). MR images were
processed using optimized VBM in Statistical Parametric Mapping
5 (SPM5) running on MATLAB R2010b (MathWorks, Natick,
MA) according to the VBM5.1-Manual (http://dbm.neuro.uni-
jena.de/vbm/vbm5-for-spm5/manual/) and as previously de-
scribed [28,29]. We screened all scans and found no gross
abnormalities, such as infarcts, hemorrhages or brain tumors, in
any of the subjects. Each image was visually examined to eliminate
images with motion or metal artifacts, and then the anterior
commissure-posterior commissure line was adjusted. The normal-
ized segmented images were modulated by multiplication with
Jacobian determinants of the spatial normalization function to
encode the deformation field for each subject as tissue volume
changes in the normal space. Finally, images were smoothed with
a 12-mm full-width, half-maximum isotropic Gaussian kernel.
Statistical analyses were performed with SPM8 software (http://
www.fil.ion.ucl.ac.uk/spm/software/spm8/). First, we performed
whole brain searches to explore the effects of the NRGN genotype
and the genotype-diagnosis interaction on GM or WM volume in
total subjects. Second, we performed separate whole brain searches
to explore the effect of the NRGN genotype on GM or WM volume
in patients with schizophrenia and in controls. The genotype effect
on GM or WM volume was assessed statistically using a multiple
regression model in SPM8. We contrasted GM or WM volume
between the genotype groups (coded as the number of rs12807809
risk T alleles: 0, 1, or 2); GM or WM volumes were correlated with
the number of risk T alleles, either positively (CC,CT,TT) or
negatively (TT,CT,CC). The genotype-diagnosis interaction on
GMorWMvolumes was assessed full factorialmodel with diagnosis
as a factor and genotype status as a covariate interacted with the
diagnosis in SPM8. Age, sex and years of education were included
as covariates of no interest into all analyses to control for
confounding variables. Non-sphericity was estimated. These
analyses yielded statistical parametric maps {SPM (t)} based on a
voxel-level height threshold of p,0.001 (uncorrected for multiple
comparisons). Clusters of more than 100 contiguous voxels were
considered in the analyses. Family-wise error (FWE) correction was
applied for multiple testing to avoid type I errors. The significance
level was set at p,0.05 (FWE corrected). Anatomic localization was
performed according to both MNI coordinates and Talairach
coordinates, which were obtained from M. Brett’s transformations
(http://www.mrccbu.cam.ac.uk/Imaging/Common/mnispace.shtml)
and presented as Talairach coordinates.
Statistical analyses
The presence of Hardy-Weinberg equilibrium was examined by
the x
2 test for goodness-of-fit using SNPAlyze V5.1.1 Pro software
(DYNACOM, Yokohama, Japan). Statistical analyses of demo-
graphic variables were performed using PASW Statistics 18.0
software (SPSS Japan Inc., Tokyo, Japan). Differences in clinical
characteristics between patients and controls or between genotypes
were analyzed using x
2 tests for categorical variables and the Mann-
Whitney U-test or Kruskal-Wallis test for continuous variables. The
significance level for all statistical tests was set at two-tailed p,0.05.
Results
Effects of the genotype and diagnosis-genotype
interaction on GM or WM regions in total subjects
First, we investigated the effects of genotype and diagnosis-
genotype interaction on GM or WM volumes in the whole brain
analyses of total subjects. We found significant effects of the risk T
allele on decreased GM volume in the right fusiform gyrus
(uncorrected p,0.001, Table 1 and blue regions in Figure 1), and
on increased WM volume in the inferior parietal lobule among
total subjects (uncorrected p,0.001, Table 1). We also found
significant genotype-diagnosis interaction on GM volume in the
left anterior cingulate gyrus and the bilateral precuneus
(uncorrected p,0.001, Table 1 and red regions in Figure 1).
However, the effects of genotype and genotype-diagnosis
interaction on these GM or WM regions did not survive after
the FWE-correction for multiple tests (FWE-corrected p.0.05).
There was no significant effect of the risk T allele on increased
GM volumes, the risk T allele on decreased WM volumes, or
genotype-diagnosis interaction on WM volume among total
subjects (uncorrected p.0.001).
Effect of the risk T allele on decreased GM regions
(TT,CT,CC)
Second, we separately investigated the effects of genotype on
GM or WM volumes in the whole brain analyses of patients with
schizophrenia and healthy controls. We found significant effects of
the NRGN genotype on GM volume in the left anterior cingulate
gyrus, the bilateral middle temporal gyrus and the left inferior
frontal gyrus among the patients with schizophrenia (uncorrected
p,0.001, Table 2 and red regions in Figure S1). We found
significant effect of the NRGN genotype on GM volume in the right
fusiform gyrus among the healthy controls (uncorrected p,0.001,
Table 2 and blue regions in Figure S1). The genotype effect on the
left anterior cingulate gyrus (BA32) in the patients with
schizophrenia remained significant even after the FWE-correction
for multiple tests at the whole brain level (T94=5.63, FWE-
corrected p=0.0042, Table 2); genotype effects on other regions
did not survive the FWE-correction (FWE-corrected p.0.05). In
patients with schizophrenia, the risk T carriers had a smaller GM
volume in the left anterior cingulate gyrus than did the non-risk C
carriers (Figure 2).
Researchers have suggested that the volume reduction of the
anterior cingulate cortex (ACC) is associated with the duration of
the illness (the length of time the patient has had schizophrenia)
[30]. In our samples, the duration of illness differed significantly
among the genotype groups in patients with schizophrenia (Table
S1). Thus, we corrected for the duration of illness. The genotype
effect on the left anterior cingulate gyrus remained significant even
after controlling for the duration of illness (T93=5.86, FWE-
corrected p=0.0017).
Effect of the risk T allele on increased GM regions
(CC,CT,TT)
We found significant effects of the NRGN genotype on GM
volume in the bilateral precuneus among the patients with
schizophrenia (uncorrected p,0.001, Table 2 and red region in
Figure S2); however, the genotype effects on these regions did not
survive after the FWE-correction for multiple tests (FWE-
corrected p.0.05). There was no significant effect of the NRGN
genotype on GM volume among the healthy controls (uncorrect-
ed p.0.001).
Effects of the risk T allele on WM regions
We found no significant effect of the risk T allele on any
decreased WM regions (TT,CT,CC) for either the patients or
controls (uncorrected p,0.001). On the other hand, we found
significant effects of the risk T allele on increased WM region
(CC,CT,TT) in the bilateral insula and middle frontal gyrus
Impact of NRGN on Brain Structure in Schizophrenia
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p values Talairach coordinates
Brain regions R/L BA CS T Uncorrected FWE x y z
GM NRGN genotipe-diagnosis interaction
Limbic Lobe
Anterior Cingulate L 32 219 4.17 ,0.001 0.33 212 40 210
Occipital Lobe
Precuneus R 31 118 3.63 ,0.001 0.90 15 264 20
Precuneus L 31 165 3.54 ,0.001 0.95 27 272 25
GM Total subjects; TT,CT,CC (higher risk,lower risk)
Temporal Lobe
Fusiform Gyrus R 20 290 4.28 ,0.001 0.25 45 230 223
GM Total subjects; TT.CT.CC (higher risk.lower risk)
no suprathreshold clusters
WM NRGN genotipe-diagnosis interaction
no suprathreshold clusters
WM Total subjects; TT,CT,CC (higher risk,lower risk)
no suprathreshold clusters
WM Total subjects; TT.CT.CC (higher risk.lower risk)
Parietal Lobe
Inferior Parietal Lobule R 616 3.72 ,0.001 0.34 44 241 25
GM: gray matter, WM: white matter, R: right, L: left, BA: Brodmann area, CS: Cluster size, FWE: family-wise error.
doi:10.1371/journal.pone.0029780.t001
Figure 1. Effects of the risk-T-allele on decreased GM regions and diagnosis-NRGN genotype interaction on GM regions. Effects of the
risk T allele on decreased GM regions (TT,CT,CC) in total subjects were shown by whinter colormap (blue areas). Diagnosis-NRGN genotype
interaction on GM regions was shown by hot colormap (red areas). There was no significant effect of the risk T allele on increased GM regions
(CC,CT,TT) among the total subjects. Each colormap shows t values corresponding to the color in the figure.
doi:10.1371/journal.pone.0029780.g001
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Table S2 and red regions in Figure S3). However, the genotype
effects on these regions did not survive after the FWE-correction
(FWE-corrected p.0.05). There was no significant genotype effect
on any increased WM region for the controls (uncorrected
p,0.001). These findings suggest that NRGN may not play a
major role in the morphology of WM.
Discussion
This is the first study to identify brain morphology associated
with genome-wide significant risk variants in NRGN for schizo-
phrenia at the whole brain level. Genotype-diagnosis interaction
on GM volume in the left ACC was found, even though the effect
did not survive after the FWE-correction. When we separately
Figure 2. Impact of the NRGN genotype on GM volume of left anterior cingulate gyrus in schizophrenia. (A) Anatomical localizations are
displayed on coronal, sagittal, and axial sections of a normal MRI spatially normalized into the Montreal Neurological Institute template (uncorrected
p,0.001, cluster size.100). A significant cluster of the genotype effect was in the left anterior cingulate gyrus in the patients with schizophrenia,
after controlling for differences in the duration of illness among genotypes. The region is shown as cross-hairline. The color bars show t values
corresponding to the color in the figure. (B) Each column shows relative gray matter volumes extracted from the left anterior cingulate gyrus
(Talairach coordinates; 212, 42, 29). We extracted a sphere with a 10 mm volume-of-interest (VOI) radius from the significant region to compare the
effects of the genotype in both the patients with schizophrenia and healthy subjects. Error bars represent the standard error.
doi:10.1371/journal.pone.0029780.g002
Table 2. Effects of NRGN genotype on GM volumes in patients with schizophrenia and in healthy controls.
p values Talairach coordinates
Brain regions R/L BA CS T Uncorrected FWE x y z
SZ; TT,CT,CC (higher risk,lower risk)
Limbic Lobe
Anterior Cingulate L 32 525 5.63 ,0.001 0.0042 212 42 29
Temporal Lobe
Middle Temporal Gyrus L 21 143 3.87 ,0.001 0.80 266 219 25
Middle Temporal Gyrus R 21 106 3.69 ,0.001 0.93 59 224 26
Frontal Lobe
Inferior Frontal Gyrus L 10 102 3.88 ,0.001 0.80 236 45 4
HC; TT,CT,CC (higher risk,lower risk)
Temporal Lobe
Fusiform Gyrus R 20 334 4.4 ,0.001 0.19 45 231 223
SZ; TT.CT.CC (higher risk.lower risk)
Parietal Lobe
Precuneus L 7 182 4 ,0.001 0.68 215 264 38
Occipital Lobe
Precuneus R 31 143 3.81 ,0.001 0.86 15 264 19
HC; TT.CT.CC (higher risk.lower risk)
no suprathreshold clusters
GM: gray matter, R: right, L: left, BA: Brodmann area, CS: Cluster size, FWE: family-wise error, SZ: patients with schizophrenia, HC: healthy controls. Significant results
[p,0.05 (FWE corrected)] are shown as bold face and underline.
doi:10.1371/journal.pone.0029780.t002
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patients with schizophrenia and healthy controls, carrying the risk
T allele of rs12807809 was associated with reduced GM volume in
the left ACC in patients with schizophrenia. The genotype effect
survived a correction for multiple comparisons at the whole brain
level. This finding applies to the patients with schizophrenia but
not to the healthy controls, and it is present even after controlling
for differences in the duration of illness among genotypes.
Significant difference on WM volume between genotypes was
not observed for any region in patients or controls.
The ACC is a functionally heterogeneous region involved in
diverse cognitive processes [30]. The functional diversity of the
ACC encompasses executive, attention, social cognitive, affective
and skeleton- and viscera-motor functions. Most MRI studies
suggest that patients with schizophrenia show reduced GM in the
ACC [30]. These reductions extend across the dorsal and rostral
divisions of the limbic and paralimbic regions of the ACC. Some
studies suggest that relatives of schizophrenia patients also show
bilateral reductions in GM volume or thickness in the ACC
[31,32]. Post-mortem findings indicate that these imaging-related
changes are accompanied by reductions in neuronal, synaptic, and
dendritic density as well as increased afferent input [30]. These
findings suggest that the GM differences observed with MRI arise
from alterations in both neuronal and non-neuronal tissue
compartments.
The GM reductions in the ACC precede the onset of psychosis
in some categories of high-risk individuals. Cross-sectional and
longitudinal studies suggest that the earliest ACC changes in
schizophrenia appear in the rostral paralimbic regions of the ACC
prior to the onset of psychosis, extend across the paralimbic
regions of the ACC during the transition to a first episode
psychosis, and spread to engulf the limbic regions of the ACC with
continued illness [30]. The regions of the genotype effect in the
present study were the paralimbic regions of the ACC. A mean
duration of illness in patients included in this study was 13.0610.4
years; these patients are considered to have established schizo-
phrenia. As the duration of illness has been related to the degree of
reduction of the ACC and because it significantly differed among
the genotype groups in our subjects, we ascertained whether the
genotype effect in the ACC is affected by variation in the duration
of illness. However, the genotype effect in the left ACC was robust
even after controlling for the duration of illness. These findings
suggest that part of the paralimbic regions of the ACC may be
attributed to the effects of the genome-wide supported variant of
NRGN in patients with schizophrenia, regardless of the duration of
illness.
NRGN is especially enriched in CA1 pyramidal neurons in the
hippocampus [33]. NRGN produced severe deficits in hippocam-
pus-dependent tasks in knock-out mice [34,35]. This evidence
suggests that NRGN may be important in neurocognitive tasks such
as learning and memory and in the morphology and function of
the hippocampus. Based on this hypothesis, Donohoe et al. tested
the relationship between schizophrenia associated with the NRGN
variant rs12807809 and cognition in Irish and German case-
control samples [36]. They did not find a significant association
between the NRGN variant and cognition in the samples. Pohlack
et al. found that homozygous T carriers had decreased activation
of the left hippocampus during contextual fear conditioning but
did not find the same result in the hippocampal structure of
Caucasian healthy volunteers [37]. We did not find a significant
association between the NRGN variant and hippocampal volume,
consistent with recent study using the ROI approach [37]. These
findings suggest that NRGN may play an important role in
hippocampal activity but not play a major role in the
neurocognition of learning and memory or in the morphology of
the hippocampus.
There were several limitations to this study. A false-positive
association could not be excluded from our study despite the
precautions for ethnic matching and corrections for multiple
testing. It is necessary to conduct further investigations to confirm
our findings in other samples with much larger sample sizes and/
or with different ethnicities and/or in relatives with schizophrenia.
A false-negative association could not be excluded in our study
because we applied a strict correction for multiple comparisons at
the whole brain level (FWE-corrected p,0.05). The regions shown
in the Supporting Information (uncorrected p,0.001) might be
helpful in further studies. It is still unclear whether this genetic
variant of the NRGN gene is associated with the expression,
transcription, splicing or translation of the gene. The lack of a
clear association makes it difficult to determine whether our results
are directly linked to the NRGN polymorphism rs12807809, to
other polymorphisms in linkage disequilibrium with this variant, or
to interaction between this genetic variant of the NRGN and other
polymorphism. As with other risk variants for schizophrenia,
clarifying the biological role of this variant through in vitro and in
vivo studies is important to improve the understanding of the
pathophysiology of schizophrenia. In addition, an extensive search
for other functional variants at this locus is needed to determine
whether rs12807809 is the most strongly associated variant for
schizophrenia in this gene.
In conclusion, we found that a genome-wide supported variant
of NRGN may be associated with brain morphological vulnerability
of the left ACC in patients with schizophrenia. Abnormalities in
ACC may partly explain the disturbances in cognitive and
emotional integration in patients with schizophrenia. Further
research will be required to clarify the function of the risk NRGN
variant on the pathophysiology of schizophrenia.
Supporting Information
Figure S1 Effect of risk-T-allele on decreased GM
regions in patients with schizophrenia and in healthy
controls. Effect of the risk T allele on decreased GM regions
(TT,CT,CC) in the patients with schizophrenia was shown by
hot colormap (red areas), while effect of the T allele on decreased
GM regions in the healthy controls was shown by winter colormap
(blue areas).
(TIF)
Figure S2 Effect of the risk-T-allele on increased GM
regions in the patients with schizophrenia. Effect of the
risk T allele on increased GM regions (CC,CT,TT) in the
patients with schizophrenia was shown by hot colormap (red
areas). There was no significant effect of the NRGN genotype on
GM volume among the healthy controls.
(TIF)
Figure S3 Effect of the risk-T-allele on increased WM
regions in the patients with schizophrenia. Effect of the
risk T allele on increased WM regions (CC,CT,TT) in the
patients with schizophrenia was shown by hot colormap (red
areas). There was no significant effect of the NRGN genotype on
WM volume among the healthy controls.
(TIF)
Table S1 Demographic information for patients with
schizophrenia and healthy controls included in the VBM
analysis.
(DOC)
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